Bausch Health Companies Inc.: directors' dealings · United States · SEC (Form 4)

About Bausch Health Companies Inc.

Bausch Health Companies Inc. is a diversified healthcare company listed on the NYSE/NASDAQ in the United States (United States), with a business mix spanning pharmaceuticals, medical devices, aesthetics, and eye health through its controlling interest in Bausch + Lomb. The company’s global headquarters are in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. For equity investors, Bausch Health stands out as a specialized healthcare platform with a broad portfolio of established brands and a meaningful presence in niche therapeutic categories. The company develops, manufactures, and markets products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, and international pharmaceuticals, and it also participates in eye health through Bausch + Lomb. Its portfolio includes branded prescription medicines, branded generics, and OTC products. Bausch Health says it sells directly or indirectly in more than 90 countries and regions, including the United States, Canada, Europe, the Middle East, Africa, Asia Pacific, and Latin America. That geographic spread gives the group a diversified revenue base, although performance remains influenced by execution in a handful of core franchises. From a competitive standpoint, Bausch Health is not a mega-cap pharmaceutical company, but it has carved out defensible positions in selected specialty markets. In U.S. medical dermatology, its Ortho Dermatologics business is described by the company as one of the largest prescription dermatology companies in the world, supporting its relevance in specialty care. Bausch + Lomb adds a major ophthalmology and vision-care component, while the core Bausch Health portfolio provides exposure to chronic and specialty therapies that tend to be less commoditized than mass-market generics. This combination makes the company a hybrid between a specialty pharma operator and a broader healthcare asset platform. Recent developments have been material. On February 18, 2026, Bausch Health reported full-year 2025 revenue of $10.27 billion and continued improvement in adjusted EBITDA, while also noting the acquisition of Shibo’s full-service aesthetics distribution business in China, which expands its footprint in aesthetic treatments. On April 29, 2026, management reaffirmed full-year 2026 guidance and highlighted continued investment in its pipeline, including larsucosterol for alcohol-associated hepatitis. The company also completed significant debt refinancing actions in 2025, an important factor for investors given Bausch Health’s historical leverage profile. Overall, the name remains a global healthcare company with a diversified product base, ongoing portfolio development, and a balance-sheet story that remains central to the investment case.